Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms

Neurobiology of Disease

Volumn 42, Issue 3, 2011, Pages 530-538

  Herring, Arne ^a   Lewejohann, Lars ^b   Panzer, Anna Lena ^b   Donath, Anja ^a,c   Kröll, Oliver ^c   Sachser, Norbert ^b   Paulus, Werner ^c   Keyvani, Kathy ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Alzheimer's disease; Amyloid plaque; Environmental enrichment; Prevention; Therapy

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; ENVIRONMENTAL ENRICHMENT; FEMALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENVIRONMENT; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; STATISTICS, NONPARAMETRIC;

EID: 79954628369     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.03.007     Document Type: Article

References (72)

1. Adlard P.A., et al. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:4217-4221.
2. Ambrée O., et al. Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways. Am. J. Pathol. 2006, 169:544-552.
3. Ansari M.A., Scheff S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J. Neuropathol. Exp. Neurol. 2010, 69:155-167.
4. Arendash G.W., et al. Environmental enrichment improves cognition in aged Alzheimer's transgenic mice despite stable beta-amyloid deposition. Neuroreport 2004, 15:1751-1754.
5. Bell R.D., et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 2007, 27:909-918.
6. Bell R.D., Zlokovic B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009, 118:103-113.
7. Bellucci A., et al. Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol. Dis. 2006, 23:260-272.
8. Berardi N., et al. Environmental enrichment delays the onset of memory deficits and reduces neuropathological hallmarks in a mouse model of Alzheimer-like neurodegeneration. J. Alzheimers Dis. 2007, 11:359-370.
9. Boche D., et al. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 2010.
10. Boche D., Nicoll J.A. The role of the immune system in clearance of Abeta from the brain. Brain Pathol. 2008, 18:267-278.
11. Boche D., et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008, 131:3299-3310.
12. Chen L., et al. Lipid peroxidation up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. J. Neurochem. 2008, 107:197-207.
13. Chishti M.A., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
14. Ciaccio C., et al. Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity. J. Mol. Biol. 2009, 385:1556-1567.
15. Costa D.A., et al. Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol. Aging 2007, 28:831-844.
16. Cotel M.C., et al. Environmental enrichment fails to rescue working memory deficits, neuron loss, and neurogenesis in APP/PS1KI mice. Neurobiol. Aging 2010.
17. Cracchiolo J.R., et al. Enhanced cognitive activity-over and above social or physical activity-is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity. Neurobiol. Learn. Mem. 2007, 88:277-294.
18. Dahlgren K.N., et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277:32046-32053.
19. Deane R., et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003, 9:907-913.
20. Doi Y., et al. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid beta neurotoxicity in in vitro and in vivo models of Alzheimer's disease. Am. J. Pathol. 2009, 175:2121-2132.
21. Dudal S., et al. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol. Aging 2004, 25:861-871.
22. Duyckaerts C., et al. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009, 118:5-36.
23. Francis B.M., et al. Object recognition memory and BDNF expression are reduced in young TgCRND8 mice. Neurobiol. Aging 2010.
24. Fryer J.D., et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 2005, 25:2803-2810.
25. Gong C.X., et al. Targeting tau protein in Alzheimer's disease. Drugs Aging 2010, 27:351-365.
26. Görtz N., et al. Effects of environmental enrichment on exploration, anxiety, and memory in female TgCRND8 Alzheimer mice. Behav. Brain Res. 2008, 191:43-48.
27. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
28. Hasegawa K., et al. Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1999, 38:15514-15521.
29. Herring A., et al. Environmental enrichment enhances cellular plasticity in transgenic mice with Alzheimer-like pathology. Exp. Neurol. 2009, 216:184-192.
30. Herring A., et al. Reduction of cerebral oxidative stress following environmental enrichment in mice with Alzheimer-like pathology. Brain Pathol. 2010, 20:166-175.
31. Herring A., et al. Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol. 2008, 18:32-39.
32. Herzig M.C., et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 2004, 7:954-960.
33. Iwatsubo T., et al. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
34. Jankowsky J.L., et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:5217-5224.
35. Jankowsky J.L., et al. Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2003, 62:1220-1227.
36. Janus C., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
37. Janus C., et al. Impaired conditioned taste aversion learning in APP transgenic mice. Neurobiol. Aging 2004, 25:1213-1219.
38. Jiang Q., et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
39. Kanekiyo T., Bu G. Receptor-associated protein interacts with amyloid-beta peptide and promotes its cellular uptake. J. Biol. Chem. 2009, 284:33352-33359.
40. Kanemitsu H., et al. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett. 2003, 350:113-116.
41. Kim J., et al. Abeta40 inhibits amyloid deposition in vivo. J. Neurosci. 2007, 27:627-633.
42. Lazarov O., et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005, 120:701-713.
43. Le R., et al. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol. 2001, 60:753-758.
44. Lesne S., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
45. Manczak M., et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
46. Marx J. Neuroscience. Preventing Alzheimer's: a lifelong commitment?. Science 2005, 309:864-866.
47. Meyer-Luehmann M., et al. A reporter of local dendritic translocation shows plaque- related loss of neural system function in APP-transgenic mice. J. Neurosci. 2009, 29:12636-12640.
48. Miners J.S., et al. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 2008, 18:240-252.
49. Miranda S., et al. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog. Neurobiol. 2000, 62:633-648.
50. Mirochnic S., et al. Age effects on the regulation of adult hippocampal neurogenesis by physical activity and environmental enrichment in the APP23 mouse model of Alzheimer disease. Hippocampus 2009, 19:1008-1018.
51. Pan W., et al. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci. 2004, 117:5071-5078.
52. Pardon M.C., et al. Repeated novel cage exposure-induced improvement of early Alzheimer's-like cognitive and amyloid changes in TASTPM mice is unrelated to changes in brain endocannabinoids levels. Neurobiol. Aging 2009, 30:1099-1113.
53. Perez A., et al. Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem. Res. 2000, 25:247-255.
54. Qiu W.Q., et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 1998, 273:32730-32738.
55. Saito T., et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med. 2005, 11:434-439.
56. Salminen A., et al. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 2009, 87:181-194.
57. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
58. Shankar G.M., et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27:2866-2875.
59. Shankar G.M., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
60. Shibata M., et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000, 106:1489-1499.
61. Sultana R., et al. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. 2009, 118:131-150.
62. Tanzi R.E., et al. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004, 43:605-608.
63. Um H.S., et al. Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. Int. J. Mol. Med. 2008, 22:529-539.
64. Vasto S., et al. Inflammation, genes and zinc in Alzheimer's disease. Brain Res. Rev. 2008, 58:96-105.
65. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
66. Walsh D.M., Selkoe D.J. A beta oligomers-a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
67. Wolf S.A., et al. Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer's disease. Biol. Psychiatry 2006, 60:1314-1323.
68. Yan P., et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 2006, 281:24566-24574.
69. Ye H., et al. Activation of large-conductance Ca(2+)-activated K(+) channels depresses basal synaptic transmission in the hippocampal CA1 area in APP (swe/ind) TgCRND8 mice. Neurobiol. Aging 2010, 31:591-604.
70. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005, 28:202-208.
71. Zlokovic B.V., et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl Acad. Sci. U.S.A. 1996, 93:4229-4234.
72. Zou K., et al. Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J. Neurochem. 2003, 87:609-619.